24 September 2012
EMA/CHMP/539767/2012
Press Office

Guidelines and concept papers

Adopted during the CHMP meeting 17-20 September 2012

The guidelines and concept papers which have been adopted during this meeting of the Committee for Medicinal Products for Human Use (CHMP) will be published shortly on the European Medicines Agency's website under Regulatory/Human/Scientific guidelines. Documents for public consultation will also be available under Document search/Public consultations.

Biologics Working Party (BWP)

Reference number	Document	Status
EMA/CHMP/BWP/457920/2012	Guideline on the use of bovine serum in the manufacture of human biological medicinal products	**3-month public consultation**

Blood Products Working Party (BPWP)

Reference number	Document	Status
EMA/CHMP/BPWP/153137/2011	Reflection paper on immune tolerance induction in haemophilia A patients with inhibitors	**3-month public consultation**[1]

Cardiovascular Working Party (CVWP)

Reference number	Document	Status
EMA/CHMP/494506/2012	Paediatric addendum to CHMP guideline on clinical investigation of medicinal products in the treatment of lipid disorders	**Adopted**

[1] This document was adopted at the July 2012 CHMP meeting

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Reference number	Document	Status
EMA/CHMP/229823/2012	Concept paper on the need for revision of the guideline of medical products used in weight control	**3-month public consultation**
CHMP/EWP/2986/03 Rev.1	Guideline on clinical investigation of medicinal products for the treatment of acute heart failure	**6-month public consultation**

Central Nervous System Working Party (CNSWP)

Reference number	Document	Status
EMA/CHMP/40072/2010	Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia	**Adopted**
EMA/CHMP/771815/2011	Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis	**6-month public consultation**

Rheumatology/Immunology Working Party

Reference number	Document	Status
EMA/CHMP/520782/2012	Concept paper on the need for revision of the guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis	**3-month public consultation**